CD8 cell-derived granzyme B may be a predictor for coronary artery involvement and MACE in Takayasu arteritis patients
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxae095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Taotao Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Capital Medical University Affiliated Anzhen Hospital, Beijing, China. Hauptthemen laut MEDLINE: Granzymes, Takayasu Arteritis, CD8-Positive T-Lymphocytes, Coronary Artery Disease. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation of China.
Abstract (Originalsprache)
Coronary artery involvement (CAI) is a special but not rare manifestation of Takayasu arteritis (TAK). Granzyme B (GzmB) is a multifunctional protease associated with the immune system and coronary artery disease. However, its role in patients with TAK and CAI remains unclear. This study investigates the role of GzmB+ cell subsets in TAK. The study included 105 TAK patients and 58 healthy controls. The percentages of different GzmB+ cells in blood samples were analyzed by flow cytometry. We found that age, age at onset, body mass index, disease duration month, hypertension, and hyperlipidemia were significantly different between TAK patients with and without CAI (P = 0.000, P = 0.038, P = 0.003, P = 0.031, P = 0.039, P = 0.000). The proportions of CD3+CD8+cells (P = 0.001) and CD3+CD4+cells (P = 0.000) in GzmB+ cells were significantly increased, while the proportion of CD3-CD56+cells (P = 0.001) in GzmB+ cells was decreased in TAK patients. The proportions of three types of GzmB+ subsets in lymphocytes (CD3+CD4+GzmB+, CD3+CD8+GzmB+, CD3+CD56+ GzmB+) were higher in TAK patients with CAI compared with those without CAI (P = 0.021, P = 0.007, P = 0.007). The increased proportion of CD3+CD8+GzmB+cells/lymphocytes was an independent risk factor for coronary involvement in TAK (OR = 4.990 [1.766–14.098], P = 0.002). Additionally, patients with a high CD3+CD8+GzmB+cells/lymphocytes ratio had a higher major adverse cardiovascular events rate than those with a low ratio in TAK (P = 0.019). Our results indicate that CD8 cell-derived Gzm B may be a predictor for CAI and major adverse cardiovascular events in TAK patients. Targeting CD3+CD8+GzmB+ lymphocytes or using GzmB inhibitors could be a potential therapeutic approach for the treatment of CAI in TAK.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Capital Medical University Affiliated Anzhen Hospital, Beijing, China.
- Beijing Institute of Heart, Lung and Vessel disease, Capital Medical University Affiliated Anzhen Hospital, Beijing, China.
- Department of cardiovascular surgery, Capital Medical University Affiliated Anzhen Hospital, Beijing, China.
ORCID-Profile: Lili Pan
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation of China
Zitieren
APA
Li, T., Gao, N., Du, J., Zhao, L., Yang, S., Zhang, Y., Zhu, J., Hu, H., Qiao, Z., Cui, W., & Pan, L. (2025). CD8 cell-derived granzyme B may be a predictor for coronary artery involvement and MACE in Takayasu arteritis patients. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae095
Vancouver
Li T, Gao N, Du J, Zhao L, Yang S, Zhang Y, et al. CD8 cell-derived granzyme B may be a predictor for coronary artery involvement and MACE in Takayasu arteritis patients. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae095
BibTeX
@article{Li2025,
author = {Li, Taotao and Gao, Na and Du, Juan and Zhao, Limin and Yang, Shiyu and Zhang, Yaxin and Zhu, Junming and Hu, Haiou and Qiao, Zhiyu and Cui, Wei and Pan, Lili},
title = {CD8 cell-derived granzyme B may be a predictor for coronary artery involvement and MACE in Takayasu arteritis patients},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxae095}
}
EUVIMED